Pirkko Tamsen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pirkko tamsen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pirkko Tamsen Today - Breaking & Trending Today

Nasdaq Nordic: Nasdaq Stockholm Welcomes OncoZenge to the Nasdaq First North Growth Market


Nasdaq Nordic: Nasdaq Stockholm Welcomes OncoZenge to the Nasdaq First North Growth Market
Stockholm, February 12, 2020 - Nasdaq (Nasdaq: NDAQ) announces that trading in
OncoZenge AB s shares (short name ONCOZ) commences today on Nasdaq First North
Growth Market. The company belongs to the Health Care segment. OncoZenge is the
8th company to be admitted to trading on Nasdaq s Nordic markets in 2021.
Oncozenge develops superior products for cancer supportive care. OncoZenge is a
Swedish pharmaceutical company founded in 2020 originating from a collaboration
between Moberg Pharma and leading clinicians from Hvidovre Hospital in Denmark.
BupiZenge can radically improve quality of life for patients with severe oral ....

Eteläuomen Läi , Kostenloser Wertpapierhandel , Moberg Pharma , Rebecka Wulfing , Adam Kosty , Pirkko Tamsen , Erik Penser Bank As Certified Adviser , Health Care , Nasdaq First North Growth , Hvidovre Hospital , Nasdaq First North , European Listings , Erik Penser Bank , Nasdaq Copenhagen , Nasdaq Helsinki , Nasdaq Iceland , Nasdaq Stockholm , About Nasdaq , Media Contact , மொபெர்க் பார்மா , ஆரோக்கியம் பராமரிப்பு , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி , நாஸ்டாக் முதல் வடக்கு , ஐரோப்பிய பட்டியல்கள் , ஏறிக் பென்சர் வங்கி , நாஸ்டாக் கோபெந்ஹேகந் ,

Moberg Pharma: Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record date for Lex Asea


Share this article
STOCKHOLM, Jan. 29, 2021 /PRNewswire/
On November 16, 2020, OncoZenge AB (publ), Moberg Pharma s subsidiary, announced that the company had secured financing of a total of approximately SEK 70 million ahead of the spin-off and separate listing on Nasdaq First North Growth Market. Today, the Board of Moberg Pharma has decided that the record date for the right to receive shares in OncoZenge shall be February 5, 2021. The Board of OncoZenge has today, with the support of an authorization from an Extraordinary General Meeting on January 21, 2021, decided on the terms for the rights issue of approximately SEK 60 million (the Rights Issue ). In addition, an indicative timetable for both the Rights Issue and the listing process on Nasdaq First North Growth Market is announced, where the first day of trading is expected to be on February 12, 2021. ....

Anna Ljung , Gernandt Danielsson Advokatbyr , Moberg Pharma , Lex Asea , Pirkko Tamsen , Erik Penser Bank , Nasdaq First North Growth , Extraordinary General Meeting , Rights Issue , Nasdaq First North Growth Market , Erik Penser , Danielsson Advokatbyr , மொபெர்க் பார்மா , லெக்ஸ் காசீ , ஏறிக் பென்சர் வங்கி , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி , அசாதாரண ஜநரல் சந்தித்தல் , உரிமைகள் பிரச்சினை , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை , ஏறிக் பென்சர் ,

OncoZenge expands the board with Hilde Furberg


OncoZenge expands the board with Hilde Furberg
Search jobs
OncoZenge expands the board with Hilde Furberg
OncoZenge AB (publ) (“OncoZenge”), Moberg Pharma AB (publ)’s subsidiary, has at an Extraordinary Shareholders Meeting today resolved on expanding the board with Hilde Furberg ahead of the listing on Nasdaq First North Growth Market, which is planned to take place during the first quarter of 2021.
Hilde Furberg (born 1958) represents Linc AB and is an independent consultant and a professional board member. She has broad senior leadership experience, coming from her over 35 years in sales, marketing, strategy and general management roles in pharmaceuticals and biotechnology. Her experience is in different areas of specialty care, and from small to large global companies. Hilde has worked in companies like Baxter and Genzyme, and she was most recently the European Head of Rare Diseases for Sanofi Genzyme. Hilde has also been a boa ....

Hilde Furberg , Anna Ljung , Moberg Pharma , Sanofi Genzyme , Pirkko Tamsen , Oslo University , Extraordinary Shareholders Meeting , Nasdaq First North Growth Market , European Head , Rare Diseases , Small Cap , Nasdaq Stockholm , மொபெர்க் பார்மா , ஒசிலோ பல்கலைக்கழகம் , அசாதாரண பங்குதாரர்கள் சந்தித்தல் , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை , ஐரோப்பிய தலை , ரேர் நோய்கள் , சிறிய தொப்பி , நாஸ்டாக் ஸ்டாக்‌ஹோல்ம் ,